IGHE and eosinophilic esophagitis: Consistently, EoE patients treated with the anti‐IgE antibody, omalizumab, failed in clinical case series and in prospective, randomized, double‐blind, placebo‐controlled studies to show a significant relieve of symptoms [123, 124].